The deal gives clinicians in PathNet's national lab network access to Valar's AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer.
SOUTH SAN FRANCISCO, Calif., March 25, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing ...
SOUTH SAN FRANCISCO, Calif., April 22, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher ...
Speculation swirled for weeks around the health of Deion Sanders, Colorado Buffaloes head coach and famed Pro Football Hall of Fame inductee, who had been notably absent from team practice. When he ...
Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...
New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The ...
Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback